Acute megakaryoblastic leukemia (AMKL) is a subtype of acute myeloid leukemia (AML) in which cells morphologically resemble abnormal megakaryoblasts. While rare in adults, AMKL accounts for 4-15% of newly diagnosed childhood AML cases 1-3 . AMKL in individuals without Down syndrome (non-DS-AMKL) is frequently associated with poor clinical outcomes. Previous efforts have identified chimeric oncogenes in a substantial number of non-DS-AMKL cases, including
RBM15-MKL1, CBFA2T3-GLIS2, KMT2A gene rearrangements, and NUP98-KDM5A [4] [5] [6] . However, the etiology of 30-40% of cases remains unknown. To better understand the genomic landscape of non-DS-AMKL, we performed RNA and exome sequencing on specimens from 99 patients (75 pediatric and 24 adult). We demonstrate that pediatric non-DS-AMKL is a heterogeneous malignancy that can be divided into seven subgroups with varying outcomes. These subgroups are characterized by chimeric oncogenes with cooperating mutations in epigenetic and kinase signaling genes. Overall, these data shed light on the etiology of AMKL and provide useful information for the tailoring of treatment.
The earliest insight into the genomic alterations that drive non-DS-AMKL occurred with the recognition of a recurrent t (1;22) found in infants 7 . Ten years after this initial report, the RBM15 and MKL1 genes involved in this translocation were identified 4, 8 . Subsequently, a high-resolution study of DNA copy number alterations (CNAs) and loss of heterozygosity (LOH) in pediatric de novo AML identified a substantial number of alterations in non-DS-AMKL cases, suggesting that additional gene rearrangements may be present in this population 9 . To define the functional consequences of these structural variations, diagnostic leukemia specimens from 14 pediatric patients were previously subjected to RNA and exome sequencing 5 . This effort identified chimeric transcripts encoding fusion proteins in 12 of the 14 cases, including a recurrent CBFA2T3-GLIS2 fusion, which correlates with a poor prognosis. In parallel, a separate non-DS-AMKL cohort was evaluated by PCR and split-signal FISH for fusion events associated with myeloid malignancies, including NUP98 fusions and KMT2A gene rearrangements (KMT2Ar) 6 . In this cohort, NUP98 fusions and KMT2Ar were identified in 15% and 10% of cases, respectively. To gain a more comprehensive understanding of the genomic alterations that lead to non-DS-AMKL, we performed RNA and/or exome sequencing on specimens from 99 patients (75 pediatric and 24 adult cases) (Supplementary Tables 1-3 ). In combination with the 14 cases previously described, the pediatric cohort described in this manuscript yields 89 cases, the largest collection of this rare malignancy to undergo next-generation sequencing to date.
Of the 93 patients for whom sufficient RNA was available for analysis, 5.5% of adult and 72.4% of pediatric cases carried a structural variant Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes l e t t e r s predicted by RNA-seq to lead to a fusion product (Supplementary Table 4 ). Ten additional fusion events in the 19 patients who lacked RNA for sequencing could be recognized by RT-PCR, FISH, or Southern blotting ( Fig. 1 and Supplementary Tables 1 and 4) . In the pediatric cohort, the most frequent previously reported fusion events included CBFA2T3-GLIS2 (18.6%), KMT2Ar (17.4%), NUP98-KDM5A (11.6%), and RBM15-MKL1 (10.5%). Previously described low-frequency non-DS-AMKL fusions identified in this expanded cohort included a case of NIPBL-HOXB9 and a novel but analogous NIPBL-HOXA9 fusion 5 . Similarly, we identified a case carrying a GATA2-HOXA10 fusion, which is comparable to the GATA2-HOXA9 fusion previously reported in a single case 5 . Chimeric transcripts not previously described included several fusions involving genes within the HOX clusters (EWSR1-HOXB8, PLEK-HOXA11-AS, BMP2K-HOXD10, and EP300-HOXA7). Collectively, fusions involving a HOX cluster gene (HOXr) occurred in 14% of patients within the pediatric cohort ( Table 1 and Supplementary Tables 1 and 4) . Many of the HOXr are predicted to lead to an in-frame functional fusion protein ( Table 1 and  Supplementary Table 4) . As proof of principle, we evaluated three of these fusion events and found all three to enhance self-renewal, as determined by an in vitro colony replating assay (Supplementary Fig. 1 ). However, several fusions involved noncoding RNA species and are predicted to result in loss of function of these regulatory transcripts (Supplementary Table 4 ). In addition, 3.5% of cases encoded nonrecurrent fusion proteins involving hematopoietic transcription factors and epigenetic regulators, including MN1-FLI1, BCR-ABL1, and MAP2K2-AF10 (Supplementary Tables 1 and 4) , and 3.5% of cases were found to have chimeric transcripts involving the cohesin gene STAG2; all of these transcripts were predicted to lead to a truncated protein (Supplementary Tables 1 and 4) . In 21% of the pediatric cases, no potentially oncogenic fusion event could be detected. However, in 50% of these latter cases, a truncating mutation in exon 2 or 3 of GATA1 was found, with 10.1% of the total pediatric cohort having such a mutation ( Fig. 1 and Supplementary Tables 1 and 3-7) .
To determine whether these fusion events contribute to gene expression patterns, we subjected samples with greater than 60% tumor purity to unsupervised clustering using the 100 genes with the greatest variance in expression as determined by s.d. (Fig. 2a,b and Supplementary  Tables 8 and 9 ). Confirming the strength of the fusions in determining gene expression signatures, the samples clustered according to fusion status: specifically, KMT2Ar, HOXr, NUP98-KDM5A, and CBFA2T3-GLIS2 cases formed distinct clusters. When analyzing expression of the HOX gene cluster, we found upregulation of the HOX gene involved in the corresponding fusion construct (Supplementary Fig. 2a) , which was often accompanied by upregulation of adjacent HOX genes. To determine whether this upregulation has downstream effects on HOX protein targets, such as PIM1, we evaluated expression of a gene set defined by HOXA9 overexpression in hematopoietic cells 10, 11 . In this analysis, the majority of target genes demonstrated the highest association with the HOXr subgroup, providing further evidence of a HOX gene expression signature ( Fig. 2c and Supplementary Fig. 2b ). When combining this subgroup with the subgroups harboring KMT2Ar and NUP98-KDM5A, chimeric oncogenes known to upregulate HOX cluster genes, roughly half of pediatric non-DS-AMKL cases carry a HOX gene expression program. These cases were distinct from those carrying the cryptic CBFA2T3-GLIS2 inversion, which clustered away from all other non-DS-AMKL cases, as previously shown 5 .
In addition to having RNA-seq data, 68 cases in the pediatric cohort had DNA available for whole-exome sequencing (WES), 30 of which Tables 1, 5 , and 6). Additionally, 18.1% of cases carried mutations in a cytokine receptor gene, the most frequent of which was the thrombopoietin receptor MPL (n = 11) that plays a role in normal megakaryoblast growth and survival 12 . In contrast, in the adult cohort (n = 24), which lacked recurrent fusion genes, the most highly recurrent mutations were in TP53 ( 0 Global association between each AMKL subgroup and HOXA9 target gene expression was estimated using the global test 21 . The contribution of each gene to overall association is indicated by the height of the bar. Bars are ranked, with the most significantly correlated genes on the left, and they are colored according to the subgroup with which each gene has the highest association. Samples with less than 60% tumor purity were not included in this analysis; as a result, no RBM15-MKL1 cases are represented.
l e t t e r s (Supplementary Table 7 ). Paired exome specimens and SNP array results were available in 40 specimens for CNA analysis to identify additional cooperating mutations ( Fig. 3b and Supplementary Table 10 ). The tumor-suppressor gene RB1 was recurrently targeted by focal deletion events (Supplementary Table 12 ), none had physical stigmata consistent with Down syndrome. Karyotypes were available for all patients and were found to be negative for constitutional trisomy 21. Four pediatric cases had matched germline DNA available with an average coverage of 110×. With the exception of one case that had evidence of low-level tumor contamination in the germline DNA specimen, GATA1 mutant calls were absent from these remission samples, including a case with 160× coverage, arguing against mosaicism in the hematopoietic compartment of these individuals. One patient had non-hematopoietic tissue available for analysis and was found to be germline mosaic for trisomy 21 (Supplementary Table 12 ) (ref. 15) . The strong association with GATA1 truncations in individuals with Down syndrome suggests cooperativity between amplification of the Down syndrome critical region (DSCR) on chromosome 21 and GATA1 mutation. Therefore, we evaluated cases for amplification of the DSCR using SNP arrays and exome read depth in paired samples. Nine of the ten GATA1-mutant cases had amplifications in the DSCR (Supplementary Table 12 ). In all cases, GATA1 mutations and chromosome 21 amplifications were in the major clone, and thus the order of acquisition could not be determined (Supplementary Table 12 ). Across the entire cohort, amplifications of chromosome 21 were found to be one of the most highly recurrent CNAs (39.2% overall; Fig. 3b and Supplementary Tables 1 and 10) . Candidate genes in this region that play a role in megakaryopoiesis include UBASH3A, LINC00478-MONC, DYRK1A, and ERG, among others [16] [17] [18] [19] [20] . GATA1-mutant cases represented a distinct subset at the gene expression level (Fig. 2a,b) , and this signature was strongly correlated with the signature found in DS-AMKL (Supplementary Fig. 5a ). Confirming cooperativity with chromosome 21, the GATA1-mutant subset significantly overexpressed chromosome 21 genes, even in comparison with other samples carrying extra copies of this chromosome (P = 5.8 × 10 −6 ; Supplementary Fig. 5b and Supplementary Table 13 ).
In combination with the RNA-seq data, these findings led us to divide our cohort into seven subsets based on genomic lesions for further analysis: CBFA2T3-GLIS2, RBM15-MKL1, NUP98-KDM5A, KMT2Ar, HOXr, GATA1, and 'other' , which is a subset comprising cases not falling into any of the aforementioned categories (Fig. 1) .
Analysis of cooperating mutations, as identified by WES and SNP arrays, showed a significant association between subgroups and recurrent mutations (P = 2.8 × 10 −8 , global test) (Fig. 3c and Fig. 6 and Supplementary Table 11); KMT2Ar often associated with RAS pathway lesions, as has been previously described (P = 0.09 for enrichment, Fisher's exact test), while JAK pathway and cohesin mutations were commonly identified in GATA1-mutant cases (P = 0.003 and P = 0.04, respectively) 22, 23 . We found that HOXr cases were significantly enriched in activating MPL mutations (P = 0.01). To further evaluate the functional consequences of HOXr and MPL mutations, we introduced the wild-type MPL gene or an MPL gene encoding one of two mutations along with a HOXr into mouse bone marrow for colony-forming assays (Supplementary Fig. 7a) . Expression of both a HOXr and either wild-type or mutant MPL failed to alter colony numbers or immunophenotype ( Supplementary Fig. 7a and data not shown). When cells were removed from cytokine-containing medium, however, we observed a growth advantage in cells containing both a HOXr and an MPL mutation (Supplementary Fig. 7b ). Activated JAK-STAT signaling, as determined by analysis of phosphorylated JAK2 and STAT5, was found in HOXr cells expressing MPL with a mutation, but not wild-type MPL or an empty vector, providing one mechanism for this growth advantage (Supplementary Fig. 8) .
Clinical outcomes for DS-AMKL are uniformly excellent, with greater than 80% disease-free survival, whereas studies on non-DS-AMKL have shown discrepant results, with the majority of cases reporting inferior survival rates as compared to cases from other AML subtypes 2, 3, [24] [25] [26] . Furthermore, the recommendation for allogeneic stem cell transplant (SCT) in first complete remission for patients with non-DS-AMKL is not uniform among pediatric cooperative groups. To understand the association between the genomic subgroups and patient outcome in pediatric non-DS-AMKL, we first used the global test to evaluate whether the subgroups each correlated with different probabilities of survival. Probability of overall survival (pOS) did not differ statistically between patients treated across continents (P = 0.8; The global association P value of 2.8 × 10 −8 (i.e., probability of random distribution) was estimated according to the global test using a multinomial regression model 21 . Individual associations: *P < 0.05, **P < 0.01, Fisher's exact test.
l e t t e r s data not shown). We observed statistically significant associations for cases with CBFA2T3-GLIS2, who showed the strongest negative association with survival, and cases with GATA1 mutations, who showed the strongest positive association with survival (P = 1.7 × 10 −5 for pOS, P = 3.4 × 10 −5 for event-free survival (pEFS); Supplementary  Fig. 9 ) (ref. 21 ). Kaplan-Meier estimates of pOS, pEFS, and cumulative incidence of relapse or primary resistance (pCIR; Gray's test, P = 1.4 × 10 −4 ) confirmed this trend (Fig. 4a-c and Supplementary  Table 15 ). Specifically, patients with CBFA2T3-GLIS2 and KMT2Ar were found to have significantly inferior pEFS and pOS when compared with other subgroups. NUP98-KDM5A cases also demonstrated a trend toward poor outcomes; however, because of small numbers of these cases, this trend failed to reach statistical significance. Conversely, the GATA1 and HOXr subgroups had significantly superior outcomes when compared with other subgroups. Of note, all GATA1-mutant cases that lacked a fusion gene were cured, mimicking the excellent outcomes observed in DS-AMKL 24 . Hence, these patients are not only biologically similar but are also clinically similar, suggesting that they may benefit from the less intensive chemotherapy regimens given to patients with DS-AMKL 15, 27 . In contrast, the two patients carrying a GATA1 mutation and a fusion gene associated with poor prognosis were non-survivors. On the basis of these results, we recommend that all pediatric patients with non-DS-AMKL be tested for the presence of GATA1 mutations, CBFA2T3-GLIS2, KMT2Ar, and NUP98-KDM5A. The chimeric oncogenes that define two of these subsets, CBFA2T3-GLIS2 and NUP98-KDM5A, are missed by conventional karyotyping and therefore require split-signal FISH or RT-PCR for detection. Although SCT was not associated with improved pEFS or pOS, a decrease in relapse-free survival (RFS) was found for patients receiving this treatment modality (hazards ratio (HR) = 0.28, P = 0.044; Supplementary Table 16 ). Therefore, patients carrying CBFA2T3-GLIS2 or KMT2Ar who have inferior outcomes may benefit from allogeneic SCT in first complete remission. While the outcomes for NUP98-KDM5A cases did not reach statistical significance, pEFS and pOS warrant close monitoring in these cases and allogeneic SCT should be considered as well. In contrast, patients lacking these lesions have outcomes on par with or superior to those for patients with other subtypes of pediatric AML, and transplantation in first remission should be reserved for those showing a poor response to induction therapy (for example, high levels of minimal residual disease). In summary, pediatric non-DS-AMKL is a heterogeneous malignancy comprising distinct subsets, as defined by next-generation sequencing, with varying outcomes. We have identified a previously unrecognized subtype characterized by diverse rearrangements in the HOX loci together with similar gene expression signatures, cooperating mutations, and clinical outcomes. Identification of key genomic events in newly diagnosed patients with non-DS-AMKL is important for risk stratification, as these lesions have therapeutic implications. Allogeneic SCT in first complete remission should be considered for patients carrying a fusion gene associated with poor prognosis, including CBFA2T3-GLIS2, KMT2Ar, and NUP98-KDM5A.
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ONLINe MeTHODS
Patient samples. Specimens were provided from multiple institutions. All samples were obtained with patient or parent/guardian-provided informed consent under protocols approved by the institutional review board at each institution. Samples were de-identified before nucleic acid extraction and analysis.
Next-generation sequencing. RNA and DNA library construction for RNA and whole-exome DNA sequencing were done according to the manufacturer's instructions using the Illumina TruSeq RNA sample preparation V2 and Nextera rapid capture exome kits, respectively. Sequencing was completed on the Illumina HiSeq 2000 according to the manufacturer's instructions. Analysis of RNA and whole-exome sequencing data, which includes mapping, coverage, and quality assessment, SNV/indel detection, tier annotation for sequence mutations, and prediction of the deleterious effects of missense mutations, has been described previously 5, 28 . ORF predictions of fusion transcripts detected by RNA-seq were validated by RT-PCR, followed by Sanger sequencing of the purified PCR products. Gene expression analysis. Transcript expression levels were estimated as fragments per kilobase of transcript per million mapped fragments (FPKM); gene FPKMs were computed by summing the transcript FPKMs for each gene using the Cuffdiff2 algorithm 29, 30 . A gene was considered 'expressed' if the FPKM value was ≥0.35 based on the distribution of FPKM values. Genes that were not expressed in any sample group were excluded from the downstream analysis. Hierarchical clustering and t-SNE were performed using the top 100 most variant genes. Prior to the analysis, we excluded genes with sex-specific expression, snoRNAs, miRNAs, and genes whose expression is correlated with inflammatory responses (Supplementary Table 11 ). All statistical analyses were performed in the R statistical environment. Unsupervised clustering. The expression levels of genes were estimated as described above. Genes that were not expressed in any sample group were excluded from the final data matrix for downstream analysis (log 2 FPKM value −1.514573), leaving 18,905 genes. To avoid disturbances of gene expression from normal bone marrow cells and on the basis of the distribution of tumor purity, samples were included that had a blast count percentage of >60%. To further eliminate contaminating gene expression, technical replicates from a sample that was either blast cell purified (SJAMLM7010964_D1, blast percentage = 93%) or unpurified (SJAMLM7010964_D1, blast percentage = 78%) were compared, and genes with high expression only in the unpurified sample (n = 25) were eliminated (Supplementary Table 11 ). In addition, genes with sex-specific expression (n = 41) and small-RNA-encoding genes (n = 279) were removed, the latter to remove variance based on the RNA extraction protocol (Supplementary Table 11 ). The final data matrix was composed of 48 samples and 18,563 genes. We performed hierarchical clustering (HC) using the top 100 most variant genes (Supplementary Table 12 ). An HC tree, with Spearman correlation as the distance metric and Ward linkage, was constructed. The distributed stochastic neighborhood embedding method implemented in R package tSNE was used to visualize the similarities between samples in 2D space.
Analysis of chromosome 21 expression levels. Genes on chromosome 21 (chr21) and those not on chromosome 21 (non-chr21) were first saved. Weakly expressed genes (mean log 2 FPKM value ≤−1) were removed. For each gene, mean expression levels in the AMKL subgroups were calculated, and subsequently log-fold changes between chr21 and non-chr21 were determined. P value was calculated using the Wilcoxon rank-sum test. Chr21 amplification status was derived from karyotype and/or copy number variation data.
Differential chr21 gene expression between samples from the non-DS GATA1-mutant subgroup (n = 5, all carrying one or more extra copies of chr21) and other non-DS AMKL samples with one or more extra copies of chr21 (n = 13) (Supplementary Table 13 ) was performed on RNA-seq count data using the R package edgeR. Similar filtering was performed, i.e., for genes with a count per million value of >2 across ≥4 samples.
Comparison of gene expression in DS-AMKL and non-DS-AMKL. DS-AMKL log-fold change gene expression data were taken from Klusmann et al. 31 . Subgroup-specific RNA expression in non-DS-AMKL was calculated using RNA-seq count data aggregated on genes from samples from unique patients with a blast count >60%, comparing each subgroup against all others using the R package edgeR 32 . Prior to the analysis, genes with sex-specific expression were removed. Data were merged and aggregated by gene symbol and gene expression values. Finally, the most significantly differentially expressed genes in both data sets (FDR < 0.2) were correlated.
Association of gene expression with HOXA9 target genes. First, upregulated targets of HOXA9 were taken from Dorsam et al. 10 . Then, association between the expression values of these genes (with the exception of those that were not expressed in either sample) and the AMKL subgroups were quantified using the global test, where group labels were used as the response variable.
Associations of AMKL subgroups with cooperating mutations. Highconfidence SNVs and indels from the initial diagnostic samples excluding mutations in GATA1 were combined with structural alterations excluding those identifying genomic subgroups and were subjected to mutational frequency analysis (Supplementary Tables 4, 6 , 9, and 15). One hypermutated sample (SJAMLM7060_D) was excluded from this analysis. Genes mutated in >4 cases (RB1, MPL, CTCF, JAK2, and NRAS) were identified. Based on these five genes, five non-overlapping proximal gene sets were constructed from mutated genes, covering 44% of identified cooperating mutations. Global association with AMKL subgroup was calculated using the global test 21 . Enrichment of gene set mutations in the AMKL subgroups was determined by one-sided Fisher's exact tests. The Circos plot was constructed using the table viewer available at http://mkweb.bcgsc.ca/tableviewer/.
Colony-forming assays. All experiments involving mice were reviewed and approved by the Institutional Animal Care and Use Committee at St. Jude Children's Research Hospital. Bone marrow from 4-to 6-week-old female C57BL/6 mice was harvested, lineage depleted, and cultured in the presence of recombinant murine SCF (rmSCF; Peprotech, 50 ng/ml), IL-3 (rmIL3; Peprotech, 50 ng/ml), and IL-6 (rmIL6; Peprotech, 50 ng/ml) for 24 h before transduction on plates coated with RetroNectin (Takara Bio Inc.). Cultured supernatants containing ecotropic envelope pseudotyped retroviral vectors were produced by transient transfection of 293T cells as previously described 33 . Mouse bone marrow cells were harvested 48 h following transduction, sorted for vector-encoded mCherry or GFP expression, and plated on methylcellulose containing IL-3, IL-6, SCF, and erythropoietin (EPO) (Stemcell Technologies) according to the manufacturer's instructions. Colonies were counted after 7 d of growth at 37 °C, harvested, and serially replated.
Affymetrix SNP arrays. Affymetrix SNP 6.0 array genotyping was performed for 14 of the 15 AMKL cases in the discovery cohort, and array normalization was performed and DNA copy number alterations were identified as previously described [34] [35] [36] [37] . To differentiate inherited copy number alterations from somatic events in leukemia blasts from patients lacking matched normal DNA, identified putative variants were filtered using public copy number polymorphism databases and a St. Jude database of SNP array data from several hundred samples 38, 39 .
Copy number alteration detection using whole-exome sequencing. The SAMtools mpileup command was used to generate an mpileup file from matched normal and tumor BAM files with duplicates removed 40 . VarScan2 was then used on the mpileup file to call somatic CNAs after adjusting for normal/tumor sample read coverage depth and GC content 41 . The circular binary segmentation algorithm implemented in the DNAcopy R package was used to identify the candidate copy number alterations for each sample 37 . B-allele frequency
